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1 
Cell cycle 
  
The cell cycle, or cell-division cycle, is the series of events that take place in a 
cell leading to its duplication. In eukaryotic cells the cell cycle can be divided in 
two periods: interphase and mitosis (M) phase. In interphase cells grow, accu-
mulating nutrients needed for mitosis and to duplicate its DNA. In the mitosis 
phase cells split themselves into two distinct cells, often called daughter cells.  
The interphase consists of three distinct phases: G1 phase, synthesis phase 
(S), G2 phase; M phase is itself composed of two tightly coupled processes: ka-
ryokinesis, in which the cell chromosomes are segregated between the two 
daughter cells, and cytokinesis, in which the cell cytoplasm divides in half form-
ing distinct cells. Activation of each phase is dependent on the proper progres-
sion and completion of the previous one. Cells that have temporarily or reversi-
bly stopped dividing are said to have entered a state of quiescence called G0 
phase (fig.1). 
Before a cell can enter cell division, it needs to take in nutrients. All of the pre-
parations are done during the interphase. The first phase within interphase, 
from the end of the previous M phase until the beginning of DNA synthesis is 
called G1 (G indicating gap), or the growth phase. During this phase the bio-
synthetic activities of the cell, which had been considerably slowed down during 
M phase, resume at a high rate. This phase is marked by synthesis of various 
enzymes that are required in S phase, mainly those needed for DNA replication. 
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Figure 1. Schematic view of cell cycle phases. 
Duration of G1 is highly variable, even among different cells of the same spe-
cies. The ensuing S phase starts when DNA synthesis commences; when it is 
complete all of the chromosomes have been replicated. Thus, during this 
phase, the amount of DNA in the cell has effectively doubled, though the ploidy 
of the cell remains the same because each chromosome has two sister chro-
matids. Rates of RNA transcription and protein synthesis are very low during 
this phase. An exception to this is histone production, most of which occurs dur-
ing the S phase. Then the cell enters the G2 phase, which lasts until the cell en-
ters mitosis. Again, significant biosynthesis occurs during this phase, mainly in-
volving the production of microtubules, which are required during the process of 
mitosis. The process of mitosis is complex and highly regulated. The sequence 
of events is divided into stages, corresponding to the completion of one set of 
activities and the start of the next. These stages are prophase, metaphase, ana-
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phase and telophase. During mitosis the pairs of chromosomes condense and 
attach to fibers that pull the sister chromatids to opposite sides of the cell. The 
cell then divides in cytokinesis, to produce two identical daughter cells (fig. 1).  
The Prophase, from the ancient Greek πρό (before) and υάσις (stage), is a 
stage of mitosis in which the chromatin condenses into a highly ordered struc-
ture called a chromosome in which the chromatin becomes visible and sister 
chromatids are attached to each other at a DNA element called the centromere. 
The two microtubule organizing center, an important organelle called centro-
some,  are pushed apart to opposite ends of the cell nucleus by the action of 
molecular motors acting on the microtubules. The nuclear envelope breaks 
down to allow the microtubules to reach the kinetochores on the chromosomes, 
marking the end of prophase. 
In the following  metaphase, from the ancient Greek μετά (between), chromo-
somes align in the middle of the cell before being separated into each of the two 
daughter cells. The centromeres of the chromosomes convene themselves on 
the metaphase plate, or equatorial plate, an imaginary line that is equidistant 
from the two centrosome poles. This  alignment is due to the counterbalance of 
the pulling powers generated by the opposing kinetochores. Only after all chro-
mosomes have become aligned at the metaphase plate, when every kineto-
chore is properly attached to a bundle of microtubules, does the cell enter ana-
phase. It is thought that one unattached or improperly attached kinetochore ge-
nerates a signal that activates the mitotic Spindle Assembly Checkpoint (SAC), 
to prevent premature progression to anaphase, even if most of the kinetochores 
have been attached and most of the chromosomes have been aligned. During 
anaphase, from the ancient Greek ἀνά (up), each chromatid moves to opposite 
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poles of the cell, the opposite ends of the mitotic spindle, near the centrosomes. 
During early anaphase, or Anaphase A, the chromatids abruptly separate and 
move toward the spindle poles, thanks to the shortening of spindle microtu-
bules. When the chromatids are fully separated, late anaphase, or Anaphase B, 
begins. This involves the polar microtubules elongating and sliding relative to 
each other to drive the spindle poles to opposite ends of the cell. Anaphase B 
drives the separation of sister chromatids to opposite poles through three 
forces. Kinesin proteins that are attached to polar microtubules push the micro-
tubules past one another. A second force involves the pulling of the microtu-
bules by cortex-associated cytosolic dynein. The third force for chromosome 
separation involves the lengthening of the polar microtubules at their plus ends. 
During telophase, from the ancient Greek "τελος" (end), two daughter nuclei 
form in the cell. The nuclear envelopes of the daughter cells are formed from 
the fragments of the nuclear envelope of the parent cell. Cytokinesis usually oc-
curs at the same time that the nuclear envelope is reforming, yet they are dis-
tinct processes.  
The passage of a cell through the cell cycle is well controlled by molecular 
events that check that each process occurs in a sequential fashion and it is im-
possible to reverse the cycle. Among the main players in animal cell cycle are 
cyclins, G1 cyclins (D cyclins), S-phase cyclins (cyclins E and A), mitotic cyclins 
(B cyclins), whose levels in the cell rise and fall with the stages of the cell cycle, 
and cyclin-dependent kinases (Cdks), G1 Cdk (Cdk4), S-phase Cdk (Cdk2),  M-
phase Cdk (Cdk1). Cdks levels in the cell remain fairly stable, but each must 
bind the appropriate cyclin in order to be activated. These complexes add 
phosphate groups to a variety of protein substrates that control processes in the 
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cell cycle. Another player is the anaphase-promoting complex (APC) also called 
the cyclosome, that triggers the events leading to cohesin destruction thus al-
lowing the sister chromatids to separate, and degrades the mitotic B cyclins.  
A rising level of G1-cyclins bind to their Cdks and signal the cell to prepare the 
chromosomes for replication. The retinoblastoma tumor suppressor pRb plays 
also a critical role in regulating G1 progression. PRb has been shown to bind 
and regulate a large number of cellular proteins, including members of the E2F 
family of transcription factors 1. E2F factors regulate the expression of many 
genes encoding proteins involved in cell cycle progression and DNA synthesis, 
including cyclins E and A, cdk1, B-myb, dihydrofolate reductase, thymidine ki-
nase, and DNA polymerase α. Binding of pRb to E2F inhibits E2F transcription-
al activation capacity and, in at least some cases, converts E2F factors from 
transcriptional activators to transcriptional repressors. Phosphorylation of pRb 
by D-type cyclin kinases results in the dissociation of pRb from E2F and the ex-
pression of the above mentioned E2F-regulated genes (fig. 2). Through the ac-
tivation of E2F, cyclin E is the next cyclin to be induced during the progression 
of cells through G1. The rising level of S-phase promoting factor (SPF), A and E 
cyclins bound to Cdk2, enters the nucleus and prepares the cell to duplicate its 
DNA and its centrosomes. As DNA replication continues, cyclin E is destroyed, 
and the level of mitotic cyclins begins to rise in G2. M-phase promoting factor, B 
cyclins with the Cdk1,  initiates assembly of the mitotic spindle, breakdown of 
the nuclear envelope, cessation of all gene transcription, condensation of the 
chromosomes taking the cell to metaphase.  
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Figure 2. G1 checkpoint: G1 Cdk-cyclin complex controls G1 checkpoint through pRb phospho-
rylation that prevents the binding and inactivation of transcription factor E2F. When E2F is then 
active, allows the transcription of numerous factors that trigger S-phase. 
At this point, the M-phase promoting factor activates the anaphase-promoting 
complex which allows the sister chromatids to separate and move to the poles, 
completing mitosis. Moreover, APC turns on synthesis of G1 cyclins (D) for the 
next turn of the cycle and degrades geminin, a protein that has kept the freshly-
synthesized DNA in S phase from being re-replicated before mitosis. This is the 
only one mechanism by which the cell ensures that every portion of its genome 
is copied once and only once during S phase. 
Separation of sister chromatids depends on the breakdown of the cohesins that 
has been holding them together. Cohesin breakdown is caused by a protease 
called separase, also known as separin. Separase is kept inactive until late me-
taphase by an inhibitory chaperone called securin. Anaphase begins when APC 
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destroys securin by tagging it with ubiquitin for deposit in a proteasome, thus 
ending its inhibition of separase and allowing separase to break down cohesin.  
Cell cycle checkpoints 
To ensure the fidelity of cell division in eukaryotic cells there are control me-
chanisms known as checkpoints. These checkpoints verify whether the 
processes at each phase of the cell cycle have been accurately completed be-
fore progression into the next phase. Multiple checkpoints have been identified, 
with some of them are less understood than others.  
The first checkpoint, called also restriction point, is located at the end of the cell 
cycle's G1 phase, just before entry into S phase, making the key decision of 
whether the cell should divide, delay division, or enter a resting stage. The re-
striction point is controlled mainly by action of the CKI- p16 (CDK inhibitor p16). 
Two families of CKI exist: the Cip/Kip family (p21Cip1/WAF1 (p21waf1), p27Kip1 
(p27) and p57Kip2 (p57)) that can act on most cyclin/cdk complexes and even 
on some kinases unrelated to cdks 2, and the INK4 family (p16INK4a (p16), 
p15INK4b (p15), p18INK4c (p18), and p19INK4d (p19)) that specifically inte-
racts with cdk4 and cdk6 but not other cdks 3. P16 inhibits the CDK4/6 and en-
sures that it can no longer interact with cyclin D1 to cause the cell cycle pro-
gression. When growth is induced, the expression of this cyclin is so high that 
they do bind. The new CDK/cyclin complex now phosphorylates pRb which re-
lieves the inhibition of the transcription factor E2F. E2F is then able to allow G1-
S phase transition (fig. 2). 
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Accurate duplication of eukaryotic genome is a challenging task, given that en-
vironment of cell growth and division is rarely ideal. Cells are constantly under 
the stress of intrinsic and extrinsic agents that cause DNA damage or interfe-
rence with DNA replication. To cope with these assaults, cells are equipped with 
DNA maintenance checkpoints to arrest cell cycle and facilitate DNA repair 
pathways. DNA maintenance checkpoints include the DNA damage checkpoint, 
that recognize and respond to DNA damage, and the DNA replication check-
point,  that monitors the fidelity of copying DNA 4. DNA damage checkpoint en-
sure the fidelity of genetic information both by arresting cell cycle progression 
and facilitating DNA repair pathways. Studies on many different species have 
uncovered a network of proteins that form the DNA damage checkpoints. Cen-
tral to this network are protein kinases of ATM/ATR family 5. These kinases 
sense DNA damage and phosphorylate Chk1 or Chk2 initiating a signal trans-
duction that culminates in cell cycle arrest, by activating tumor suppressor pro-
tein TP53 or  by inactivation of the Cdc25 phosphatase, in order to induce DNA 
repair.  
In response to DNA damage, the TP53 protein is stabilized and activated as a 
transcription factor. The p21waf1 gene promoter contains a TP53-binding site 
that allows TP53 to transcriptionally activate the p2 waf1 gene. Induction of p21 
waf1 inhibits cell cycle progression, blocking G1 transition by inhibiting a variety 
of cyclin/cdk complexes and by halting DNA synthesis through PCNA binding 3 . 
Cell Division Cycle 25 (CDC25) phosphatases dephosphorylate and activate 
cyclin-dependent kinase CDK–cyclin complexes, such as CDK2–cyclin E at the 
G1–S transition or CDK1–cyclin B at the entry into mitosis, thus allowing cata-
lysis and substrate phosphorylation. The phosphorylation induced by the 
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ATM/ATR pathway  inhibits CDC25 and consequently inactivates CDK–cyclin 
complexes (fig. 3). 
Damaged template, protein complexes bound to DNA, and poor supply of 
dNTPs are among the many obstacles that must be overcome to replicate ge-
nome. All of these situations can stall replication forks. Stalled forks pose grave 
threats to genome integrity because they can rearrange, break, or collapse 
through disassembly of the replication complex 6. The pathways that respond to 
replication stress are signal transduction pathways that are conserved across 
evolution 7,8. Atop of these pathways are also ATM/ATR family kinases. These 
kinases together with a trimeric checkpoint clamp (termed 9-1-1 complex) and 
five-subunit checkpoint clamp loader (Rad17-RFC2-RFC3-RFC4-RFC5) senses 
stalled replication forks and transmit a checkpoint signal 4. One of major func-
tions of replication checkpoint is to stabilize and protect replication forks 9. The 
protein kinases Chk1 and Chk2 are critical effectors of the replication check-
point 10. 
In order to prevent transmission of DNA damage to daughter cells, the cell cycle 
is arrested via inactivation of the CDC25 phosphatase (fig. 3). The spindle as-
sembly checkpoint (SAC) is an active signal produced by improperly attached 
kinetochores. In the absence of kinetochore microtubules in prometaphase, 
several activities converge on the creation of the mitotic checkpoint complex 
(MCC), which is an anaphase-promoting complex/cyclosome (APC/C) inhibitor 
composed of BUB3 together with MAD2 and MAD3 bound to Cdc20. The Au-
rora-B, Cyclin-Dependent Kinase-1 (CDK1) and budding uninhibited by benzi-
midazole (BUB)1 kinases might stimulate directly the formation of the MCC. 
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Figure 3. DNA maintenance and DNA damage checkpoints. 
The closed MAD2 (C-MAD2)–MAD1 complex is recruited to unattached kineto-
chores and recruits open MAD2 (O-MAD2). This O-Mad2 changes its conforma-
tion to C-Mad2 and binds Mad1. The Mad1/C-Mad2 complex is responsible for 
the recruitment of more O-Mad2 to the kinetochores, which changes its confor-
mation to C-Mad2 and binds Cdc20 in an auto-amplification reaction. This se-
questration of Cdc20 is essential to maintain active the spindle assembly 
checkpoint. In a separate branch of the SAC response, centromere protein 
(CENP)-E binds and activates BUBR1 at unattached kinetochores. On microtu-
bule–kinetochore attachment, a mechanism of 'stripping' based on the pole-
ward-directed microtubule-motor activity of the dynein–dynactin complex starts 
removing SAC proteins from kinetochores. The ability of CENP-E to activate 
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BUBR1 also subsides on formation of stable microtubule–kinetochore attach-
ments. All this results in APC activation and anaphase progression 11. 
 
 
Figure 4. The spindle assembly checkpoint (SAC) network 
11
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Epigenetics 
The term epigenetics was first proposed by Conrad Waddington to designate 
the study of the processes by which the genetic information of an organism, de-
fined as the genotype, interacts with the environment in order to produce its ob-
served traits, defined as the phenotype 12. More recently, the term has been 
used to define  the study of heritable changes in genome function that occur 
without a change in DNA sequence, hence the name epi- (Greek: επί- over) -
genetics. When Waddington coined the term the physical nature of genes and 
their role in heredity was not known; he used it as a conceptual model of how 
genes might interact with their surroundings to produce a phenotype. These two 
definitions are closer than they seem because an individual's cells all share the 
same linear sequence of DNA nucleotides, the genome, but different cell types 
are characterized by the presence of different chromatin flavors of this genome, 
the epigenomes, that specify the characteristic functions of each cell type and 
allows the maintenance of the memory of these functions through cell division. 
Epigenetic inheritance represents a critical mechanism that allows a remarkably 
stable propagation of gene activity states over many cell generations. The field 
of epigenetics has been receiving remarkable attention over recent years, owing 
to the awareness that epigenetic inheritance is essential for development and 
critical cellular processes such as gene transcription, and differentiation. Epige-
netic mechanisms are versatile and adapted for specific cellular memory func-
tion not only during development but also during life-time.  
Epigenetic mechanisms act to change the accessibility of chromatin to tran-
scriptional regulation locally and globally via modifications of the DNA and by 
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modification or rearrangement of nucleosomes. In this way epigenetic pro-
gramming is crucial in mammalian development, and stable inheritance of epi-
genetic settings is essential for the maintenance of tissue- and cell-type- spe-
cific functions 13. With the exception of controlled genomic rearrangements, all 
other differentiation processes are initiated and maintained through epigenetic 
modifications. Therefore, epigenetic gene regulation is characterized overall by  
a high degree of integrity and stability. Perturbation of epigenetic balances may 
lead to alterations in gene expression, ultimately resulting in cellular transfor-
mation and malignant outgrowth.  
Epigenetic information that fulfils the criterion of heritability are generally classi-
fied into two distinct types: DNA methylation and histone modifications (fig. 5). 
 
Figure 5. Epigenetic mechanisms 
14
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Histone modifications 
Genes may exist in two structural conditions, active or inactive state, indepen-
dently of their sequence. Genes are found in the active state only in cells where 
they are expressed. The change of structure precedes the act of transcription 
and indicates that the gene is transcribable. This suggest that the acquisition of 
the active state must be the first step in gene expression. Active genes are 
found in domains of euchromatin with a preferential susceptibility to nucleases, 
and, in fact, hypersensitive sites are created at promoters before a gene is acti-
vated. More recently it has turned out that there is an intimate and continuing 
connection between initiation of transcription and chromatin structure. Indeed 
some activators of transcription directly modify histones; in particular, acetyla-
tion is correlated with gene activation. On the other hand some repressor of 
transcription function by deacetylating histones. So a reversible change in the 
histone structure in the vicinity of the promoter is involved in the control of gene 
expression. But the acetylation/deacetylation is only one of the numerous modi-
fications that histones  can be subjected to. Generally, histone modifications are 
distinguished in ATP-dependent and ATP-independent, depending on whether 
they need or not the energy derived by ATP hydrolysis to function.  
 
ATP-dependent chromatin remodelers use the energy to disrupt protein-protein 
and protein-DNA contacts in order to release histones from chromatin. When 
histones are released from DNA other proteins, such as transcription factors 
and RNA polymerase, can bind. In vitro three types of remodelling changes 
have been described: histone octamers may slide along DNA; the spacing be-
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tween histone octamers may be changed; and the most extensive change is 
that an octamer(s) may be displaced entirely from DNA to generate a nu-
cleosome-free gap.  
SWI/SNF was the first remodeling complex to be identified. SWI/SNF com-
plexes can remodel chromatin in vitro without overall loss of histones or can 
displace histone octamers. Both types of reaction may pass through the same 
intermediate in which the structure of the target nucleosome is altered, leading 
either to reformation of a remodeled nucleosome on the original DNA or to dis-
placement of the histone octamer to a different DNA molecule. The SWI/SNF 
complex alters nucleosomal sensitivity to DNAase I at the target site, and in-
duces changes in protein-DNA contacts that persist after it has been released 
from the nucleosomes. The SWI2 subunit is the ATPase that provides the en-
ergy for remodeling by SWI/SNF.   
Remodeling complexes do not themselves contain subunits that bind specific 
DNA sequences. This suggest that they are recruited by activators or repres-
sors of transcription. The transcription factor Swi5p activates the HO locus in 
yeast. Swi5p enters nuclei toward the end of mitosis and binds to the HO pro-
moter. It then recruits SWI/SNF to the promoter. Then Swi5p is released, lea-
ving SWI/SNF at the promoter. This means that a transcription factor can acti-
vate a promoter by a hit and run mechanism, in which its function is fulfilled 
once the remodeling complex has bound 15 (fig. 6). 
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Figure 6. Yeast HO promoter activation 
16
. 
It is not always the case, however, that nucleosomes must be excluded in order 
to permit initiation of transcription. Some activators can bind to DNA on a nu-
cleosomal surface. Nucleosomes appear to be precisely positioned at some 
steroid hormone response elements in such a way that receptors can bind. Re-
ceptor binding may alter the interaction of DNA with histones, and even lead to 
exposure of new binding sites. The exact positioning of nucleosomes could be 
required either because the nucleosome presents DNA in a particular rotational 
phase or because there are protein-protein interactions between the activators 
and histones or other components of chromatin.  
 
ATP-independent histone modifications are enzymes that induce post-transla-
tional modifications on histones. Histones can be acetylated/deacetylated, 
phosphorylated/dephosphorylated, methylated, SUMOylated or ADP-ribosy-
lated, and every modification has a different meaning depending on its nature 
and position (histone code) 17. The histone modifications may directly affect nu-
cleosome structure or create binding sites for the attachment of nonhistone pro-
teins that change the properties of chromatin 18,19. Modifications take place in 
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the N-terminal tails of the histones, especially H3 and H4. The histone tails con-
sist of the N-terminal 20 amino acids, and extend from the nucleosome between 
the turns of DNA. The modifications alter positive charge led by lysine and ar-
ginine (fig. 7). The histone modifications may directly affect nucleosome struc-
ture or create binding sites for the attachment of nonhistone proteins that 
change the properties of chromatin. Modification can be a local event, for ex-
ample, restricted to nucleosomes at the promoter. Or it can be a general event, 
extending for example to an entire chromosome.  
All core histones can be acetylated but the major targets are lysines in the N-
terminal tails of histones H3 and H4. Acetylation occurs in two different situa-
tions: during DNA replication and when genes are activated.  
When chromosomes are replicated, during the S phase of the cell cycle, his-
tones are transiently acetylated before they are incorporated into nucleosomes. 
It is known that histones H4 and H3 are acetylated when they are associated 
with one another in the H32-H42 tetramer. The tetramer is then incorporated into 
nucleosomes. Quite soon after, the acetyl groups are removed.  
Acetylation is reversible. Each direction of the reaction is catalyzed by a specific 
type of enzyme. Enzymes that can acetylate histones are called histone acetyl-
transferases or HATs; the acetyl groups are removed by histone deacetylases 
or HDACs (fig. 7). There are two groups of HAT enzymes: group A describes 
those that are involved with transcription; group B describes those involved with 
nucleosome assembly. Two inhibitors have been useful in analyzing acetylation. 
Trichostatin A (TSA) and butyric acid inhibit histone deacetylases, and cause 
acetylated nucleosomes to accumulate.  
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Figure 7. Acetylation of lysines. Lysine has a positively charged amino group in its side chain 
that can be acetylated by HATs. This reaction can be reversed by HDACs. The positive charge 
on the histone tails should increase the potential for electrostatic interactions with the negatively 
charged phosphate backbone of DNA. 
One of the first general activators to be characterized as an HAT was 
p300/CBP, a co-activator that links an activator to the basal apparatus. 
p300/CBP acetylates the N-terminal tails of H4 in nucleosomes. Another co-ac-
tivator, called PCAF, preferentially acetylates H3 in nucleosomes. p300/CBP 
and PCAF form a complex that functions in transcriptional activation. Acetyla-
tion may be necessary to loosen the nucleosome core. At replication, acetyla-
tion of histones could be necessary to allow them to be incorporated into new 
cores more easily. At transcription, a similar effect could be necessary to allow 
a related change in structure, possibly even to allow the histone core to be dis-
placed from DNA. Alternatively, acetylation could generate binding sites for 
other proteins that are required for transcription. In either case, deacetylation 
would reverse the effect.  
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Histone methylation is considered as a process that maintains epigenetic me-
mory. In particular, methylation of lysines of tails extending from the nu-
cleosomes is a crucial event for transcriptional regulation, X chromosome inac-
tivation, DNA methylation and heterochromatin formation at centromeric and te-
lomeric regions of chromosomes 20,21.  This reaction is catalyzed by Histone 
Methyl-Transferases (HMTs), and can induce both the activation and the re-
pression of  gene transcription.  
Methylation of H3 9Lys is a feature of condensed regions of chromatin, including 
heterochromatin as seen in bulk and also smaller regions that are known not to 
be expressed. The histone methyl-transferase enzyme that targets this lysine is 
called SUV39H1. Other histone methyl-transferases act on arginine. In addition, 
methylation may occur on 79Lys in the globular core region of H3; this may be 
necessary for the formation of heterochromatin at telomeres 17.  
DNA methylation 
DNA methylation refers to a covalent modification of the cytosine base located 
at 5‟ to a guanine base in a CpG dinucleotide.  
Around 2-7% of the cytosines of animal cell DNA are methylated and the majo-
rity of the CG sequences are methylated. Usually the C residues on both 
strands of this short palindromic sequence are methylated, a condition known 
as fully methylated. But after DNA replication each daughter duplex has one 
methylated strand and one unmethylated strand. Such a site is called hemi-
methylated. The perpetuation of the methylated site now depends on what hap-
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pens to hemimethylated DNA. If methylation of the unmethylated strand occurs, 
the site is restored to the fully methylated condition. However, if replication oc-
curs first, the hemimethylated condition will be perpetuated on one daughter 
duplex, but the site will become unmethylated on the other daughter duplex. 
The methylation consists in the addition of a methyl group to the 5 position of 
the cytosine pyrimidine ring. The transfer of a methyl group from S-adenosyl-L-
methionine (SAM) to cytosine in CpGs is catalyzed  by several DNA methyl-
transferase (DNMTs) (fig. 8).  
 
Figure 8. Conversion of cytosine to 5-methylctosine by methyl-transferase (DNMT). DNMT ca-
talyses the transfer of a methyl group (CH3) from S-adenosyl methionine (SAM) to the 5-carbon 
position of cytosine. 
There are two types of DNA methylase, whose actions are distinguished by the 
state of the methylated DNA. To modify DNA at a new position requires the ac-
tion of the de novo methylase, which recognizes DNA by virtue of a specific se-
quence. It acts only on unmethylated DNA, to add a methyl group to one strand. 
There are two de novo methylases (Dnmt3A and Dnmt3B) in mammals; they 
have different target sites, and both are essential for development.  
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A maintenance methylase acts constitutively only on hemimethylated sites to 
convert them to fully methylated sites. Its existence means that any methylated 
site is perpetuated after replication. There is one maintenance methylase 
(Dnmt1) in mammals, and it is essential: mouse embryos in which its gene has 
been disrupted do not survive past early embryogenesis 22. Maintenance methy-
lation is virtually 100% efficient.  
DNMT1, DNMT3A and DNMT3B have a regulative domain at the N-terminus 
and a catalytic one at the C-terminus, separated by a little fragment made up 
with GK dinucleotide repeats (fig. 9).  
 
Figure 9. Members of DNMT family 
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The catalytic activity of DNMT1 needs the interaction between the two domains 
and the C-terminus alone is useless.  On the contrary the C-terminus of 
DNMT3A and DNMT3B is functional alone too 23. Methylation has various types 
of targets. Gene promoters are the most common target. The promoters are 
methylated when the gene is inactive, but unmethylated when it is active. The 
presence of m5CpG dinucleotides in the first gene exon or promoter may have 
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an effect on gene transcription in a direct or indirect manner. The direct mecha-
nism involves the interference of m5CpG dinucleotides with transcription factors 
binding to a promoter. However, the indirect mechanism of gene regulation is 
preceded by DNA binding m5CpG dinucleotide-specific proteins which block the 
interaction of transcription factors with certain DNA sequences 24. These protein 
suppressors of promoters mainly include MBDs (m5CpG binding Domain pro-
teins) and m5CpG-binding proteins (MeCPs) 25. These proteins are able to form 
complexes with HDAC, co-repressor (Sin3a) and ATP-dependent chromatin 
remodeling proteins, which are involved in the stabilization of heterochromatin 
structure. The absence of Dnmt1 in mouse causes widespread demethylation at 
promoters, and it is assumed this is lethal because of the uncontrolled gene ex-
pression 22. Satellite DNA is another target. Mutations in Dnmt3B prevent me-
thylation of satellite DNA, which causes centromere instability at the cellular 
level. Mutations in the corresponding human gene cause the ICF (Immunodefi-
ciency, Centromeric instability, Facial abnormalities) syndrome 26.  
Once a site has been methylated, there are two possible ways to generate de-
methylated sites. One is to block the maintenance methylase from acting on the 
site when it is replicated. After a second replication cycle, one of the daughter 
duplexes will be unmethylated. The other is actively to demethylate the site. It is 
known that active demethylation can occur to the paternal genome soon after 
fertilization 27, but it is not known what mechanism is used.  
The pattern of germ cells methylation is established in each sex during ga-
metogenesis by a two stage process: first the existing pattern is erased by a 
genome-wide demethylation; second the pattern specific for each sex is then 
imposed. All allelic differences are lost when primordial germ cells develop in 
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the embryo; irrespective of sex, the previous patterns of methylation are erased, 
and a typical gene is then unmethylated. In males, the pattern develops in two 
stages. The methylation pattern that is characteristic of mature sperm is estab-
lished in the spermatocyte. But further changes are made in this pattern after 
fertilization. In females, the maternal pattern is imposed during oogenesis, when 
oocytes mature through meiosis after birth. The specific pattern of methyl 
groups in germ cells is responsible for the phenomenon of imprinting, which de-
scribes a difference in behaviour between the alleles inherited from each par-
ent.  
Finally, it is clear that a generalized mechanism of transcriptional control in res-
ponse to epigenetic modifications exists. In the silent promoter, genomic se-
quencing and chromatin immunoprecipitation experiments clearly display a hy-
permethylated sequence enriched with MeCP2-HDAC repressor complexes. In-
hibitors of DNA methylation and histone deacetylase activity can alleviate this 
dominant repression pathway. Histone hyperacetylation mediated by deacety-
lase inhibitors have no effect on the transcription levels of the hypermethylated 
gene (fig. 10).  
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Figure 10. Generalized mechanism of transcriptional control in response to epigenetic modifica-
tions. Nucleosome structures are simplified in this model by illustrating the DNA coil (red) 
wrapped around the histone core (yellow) 
19
. 
These results clearly demonstrate that histone hyperacetylation is not an over-
riding mechanism of control over DNA methylation. However, 5azaCitidine in-
duced DNA demethylation causes some release of MeCP2-HDAC complexes 
from promoter chromatin and hyperacetylation of histone tails by TSA can reac-
tivate the gene. Stable transcription complexes form on hyperacetylated chro-
matin and allow the basal machinery access for transcriptional activation 19 (fig. 
10). Moreover it is also evident that the epigenetic factors cooperate in order to 
establish an active or inactive chromatin domain. The order of recruiting is alter-
native and it may happen that DNA methylation favours histone modification 
and vice versa 28 (fig. 11). 
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Figure 11. Integrative epigenetic gene repression. (Top) DNA methylation drives histone modifi-
cation; (Bottom) Histone modification directs DNA methylation 
28
. 
DNA methyl-transferase 1 (DNMT1) 
DNMT1 is the major enzyme responsible during replication for maintenance of 
the DNA methylation pattern. During the replication of eukaryotic genomic DNA, 
approximately 40 million m5CpG dinucleotides are converted into the hemi-
methylated state in the newly synthesized DNA strand. These hemimethylated 
CpG sites must be methylated precisely to maintain the original DNA methyla-
tion pattern. DNMT1 is located at the replication fork and methylates newly bio-
synthesized DNA strands directly after the replication round 29 (fig. 12). DNMT1 
displays a 5- to 40-fold higher activity in vitro for hemimethylated DNA than for 
unmethylated DNA 29,30. However, this enzyme also exhibits de novo methyla-
tion activity in vitro 31 or stimulated by DNMT3A 32 .  
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Figure 12. Hypothetical models by which CpG methylation can contribute to the propagation of 
a silent chromatin structure. Dnmt1 recognizes hemimethylated DNA, which is generated during 
the replication of methylated DNA, and binds DNA at replication forks with HDAC2 
33
. 
Its structure indicates that the DNMT1 gene could have been formed during the 
fusion of a prokaryotic DNMT gene with a mammalian DNA binding protein 
gene 34,35. Mammalian DNMT1 is also composed of at least three major struc-
tural elements. The first 621 amino acids of the N-terminus are not essential for 
DNMT1 activity 36. However, the N-terminal DNMT1 domain is essential for dis-
crimination between hemimethylated and unmethylated DNA strands and is res-
ponsible for a decrease in de novo methylation activity. The charge-rich motif of 
the N-terminal domain of DNMT1 interacts with DMAP1 and represses tran-
scription without the participation of HDAC 37. The DNMT1 N-terminal domain 
can also interact with other proteins, including the proliferating cell nuclear anti-
gen (PCNA) 38, retinoblastoma protein pRb 39, HDAC1 or HDAC2 40. The N-
terminus of DNMT1 can also recognize the MBD1, MBD3, MeCP2 and HP1 
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proteins. The interaction of DNMT1 with numerous protein suppressors of pro-
moters suggests that this DNA methyl-transferase is also a crucial element of 
the transcription suppression complex. 
The ATRX zinc finger motifs and the PCNA-binding domain (PBD) of DNMT1 
also interact with DNA and PCNA respectively during replication. This causes a 
better presentation of targeting sequences (TS) which stabilizes the replication 
foci and induces an increase in the biosynthesis rate of new DNA strands 41. 
The primary structure of human DNMT1 suggests that the entire catalytic site of 
this enzyme is composed of 500 amino acids and is located at the C-terminal 
domain 36. 
Although DNMT1 is constitutively expressed in mammalian cells, regulation of 
its activity has to be coordinated with biological processes and therefore must 
be tightly regulated in the cell cycle. DNMT1 promoter is a TATA-less one and 
therefore its transcriptional activity is highly dependent on the binding of tran-
scription factors to the basal promoter region. The E2F-binding site located 
within the transcription initiation region is critical for the regulation of DNMT1 
transcription in proliferating cells via the E2F1/pRb pathway 42. Moreover, it has 
been described that the APC/β-catenin pathway negatively regulates DNMT1 
expression in human cancer cells 43. Several groups had also independently re-
ported an inverse relationship between DNMT1 and p21waf1 expression in 
mammalian cells, which strongly suggest that the two proteins may be linked in 
a regulatory pathway. DNMT1 has been shown to repress p21waf1 in transcrip-
tional regulation 44, through UHRF1 (Ubiquitin-like, containing PHD and RING 
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fingers domains 1) 45, and vice versa p21waf1 negatively regulates DNMT1 ex-
pression by modulating p300 44. Together these pathways may play a pivotal 
role to ensure regulated DNMT1 expression and DNA methylation in mamma-
lian cell division.  
DNMT1 is an essential gene during mammalian development 22, probably be-
cause it is fundamental for both DNA replication 38 and maintaining methylation. 
It has most recently been implicated also in cancer, since it is found deregulated 
in lots of human cancers, such as colorectal 46, breast 47, lung 48 and retinoblas-
toma 49 cancers, but its role on tumor progression is not exactly understood yet. 
Epigenetics and Cancer 
Cancer is traditionally viewed as a primarily genetic disorder, however it is 
nowadays recognised as a genetic and epigenetic disease. Genetic changes 
and aneuploidy are associated with alterations in DNA sequence, and they are 
a hallmark of the malignant process. Epigenetic alterations are universally pre-
sent in human cancer and result in heritable changes in gene expression and 
chromatin structure over many cell generations without changes in DNA se-
quence, leading to functional consequences equivalent to those induced by ge-
netic alterations. Aberrant epigenetic events affect multiple genes and cellular 
pathways in a non-random fashion and this can predispose to induction and ac-
cumulation of genetic changes in the course of tumour initiation and progression 
50. The first link between epigenetics and cancer was demonstrated in 1983, 
when it was shown that the genomes of cancer cells are hypomethylated rela-
tive to their normal counterpart 51. Since that discovery, a plethora of studies re-
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ported aberrant epigenetic patterns, accompanied by silencing of tumour sup-
pressor genes and other cancer-associated genes in a variety of human can-
cers. One important conclusion that emerged from numerous screenings is that 
epigenetic events, similar to genetic changes, are associated with virtually every 
step of tumour development and progression. In addition, in many cancer types, 
epigenetic changes were found to occur early and precede genetic changes in 
the course of tumour development 50.  
 
Imbalance of histone acetylation/deacetylation in gene promoter regions con-
tributes to the deregulation of gene expression and has been associated with 
carcinogenesis and cancer progression. Both, histone acetylases and deacety-
lases have central roles in regulating the access and recruitment of transcription 
factors to DNA regulatory elements and in the regulation of other post-transla-
tional modifications at the lysine residues. The aberrant targeting of HAT or 
HDAC activity to specific gene promoters can result from the fusion of transcrip-
tion factors with protein domains that retain co-repressor or co-activator binding 
capacity. Acute promyelocytic leukemia and acute myeloid leukemia are caused 
by chromosomal translocations leading to the expression of transcription factors 
fused to the nuclear receptor RAR or to the zinc finger nuclear protein ETO, res-
pectively, which contain co-repressor interaction domains. The progression of 
these leukemias is linked to the abnormal recruitment of the N-CoR/SMRT co-
repressor complex containing histone deacetylase activity which acts by block-
ing differentiation and allowing uncontrolled growth of hematopoietic cells. More 
recent studies demonstrate that the transcriptional repression of target genes by 
 
30 
fusion proteins in leukemia is reinforced by epigenetic modifications such as 
DNA methylation 17.    
 
DNA methylation aberrations are also a key event in cancer. There are several 
distinct mechanisms by which aberrant levels and patterns of methylated CpG 
dinucleotides may trigger genetic changes and contribute to tumourigenesis. 
These include the increased mutability of methylated cytosines, silencing of tu-
mour-suppressor genes, activation of oncogenes and genomic instability.  
It has long been hypothesized that the presence of methylated CpG sequences 
per se are the major cause of mutability in mammalian genomes. The impor-
tance of the 5-methylcytosine (5-mC) of the CpG sites in cellular functions is re-
flected by the fact that it is referred to as the “fifth” base of DNA that forms “the 
DNA methylation code” 52. However, 5-mC constitutes a threat to the genome 
due to its intrinsic instability. Because it is prone to spontaneous hydrolytic de-
amination under physiological conditions, 5-mC is considered as a potent en-
dogenous mutagen. The spontaneous hydrolytic de-amination of 5-mC results 
in thymine. Thus, C to T transition will be fixed after DNA replication 50.  
Methylation pattern defects include genome wide hypomethylation and localised 
aberrant hypermethylation of CpG islands. These imbalances can be present 
together in a single tumour, though the net effect is usually a decrease in total 
methylation levels. Whether genome hypomethylation and CpG island hyper-
methylation are linked by a common underlying mechanism or result from dis-
tinct abnormalities in the cancer cell is currently unknown. However, we do 
know that hypomethylation and hypermethylation occur at specific but distinct 
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sites within the cancer cell genome, suggesting different aetiologies (fig. 13). 
Hypermethylation in tumor cells occurs at CpG islands, most of which are un-
methylated in normal somatic cells, and the resulting changes in chromatin 
structure effectively silence transcription (fig. 13). Genes involved in cell-cycle 
regulation (p16 53, p21waf1 54), tumor invasion (E-caderin 55), DNA repair 
(hMLH156), cell signalling, transcription (BRCA 57) and apoptosis are found 
aberrantly hypermethylated and silenced in nearly every tumor type 52,58. This 
provides tumor cells with a growth advantage and allows them to metastasize . 
In tumors with a well defined progression, such as colon cancer, aberrant hy-
permethylation is detectable in the earliest precursors lesions, indicating that it 
directly contributes to transformation and is not a late event that arises from ge-
netic alterations 58,59.  
Hypomethylation in tumor cells is primarily due to the loss of methylation from 
repetitive regions (fig. 13)  of the genome causing both oncogenes and mobile 
DNA activation and  genome instability. 
Figure 13. DNA methylation and cancer 
58
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Hypomethylation in human cancers is causally related to transcriptional activa-
tion of a large group of genes of the MAGE, GAGE, CTAG/LAGE, and SAGE 
families. These unrelated gene families are located on the X chromosome and 
their cellular function is unknown. The promoters of MAGE type genes have an 
intermediate density of CpGs and may constitute a unique class of promoters 
that fall somewhere between the constitutively unmethylated CpG island pro-
moter and the conditionally methylated CpG poor promoter. MAGE promoter 
demethylation, possibly as a consequence of genome wide hypomethylation, 
leads to transcriptional activation of MAGE genes in cancer cells 52.  
In fact, DNA hypomethylation in tumors has been associated with transcriptional 
activation of an unexpectedly low number of genes, suggesting that most tis-
sue-specific genes use regulatory mechanisms other than DNA methylation for 
selective repression. It is now considered that the major contribution of genome 
hypomethylation to tumor development is the enhancement of genomic instabi-
lity 60, and that hypomethylation of retrotransposons and pericentromeric re-
peats is responsible for this genomic destabilization 61.   
The timing of genomic DNA hypomethylation and relationship with promoter 
specific hypermethylation in cancer are important step in determining the 
mechanism and its significance in carcinogenesis. A number of studies found 
no significant correlation between the presence of DNA hypomethylation and 
hypermethylation in a variety of cancers, suggesting that the two events are not 
connected 62. However, since global DNA hypomethylation has been observed 
in most cancers assayed, including some benign tumours, it is believed by 
some authors to constitute an early event in transformation, possibly via karyo-
typic instability 63,64. 
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Aneuploidy and Tumorigenesis 
 
Aneuploidy, an alteration in the number of whole chromosomes, is recognized 
as a trait of cancer cells. It occurs in 90% of solid tumors and 75% of hemato-
poietic cancers 65. Even in 1914, German biologist Theodor Boveri postulated 
that aneuploidy, arising from altered cell division might lead to oncogenesis.  
Whether aneuploidy is a cause or consequence of cancer is one of the long-
standing question in cancer biology and still subject of debate. Part of the diffi-
culty in understating the role of aneuploidy in cancer lies in the big paradox that 
an abnormal number of chromosomes is initially disadvantageous for mamma-
lian cells 66,67. As a consequence only in rare cases, such as trisomy 21, imba-
lanced number of chromosome is compatible with life. However, many studies  
indicate that the effects of chromosome gains and losses are not the same and 
organisms have much less tolerance for chromosome losses that for gains. The 
likely reason is that losses of chromosomes means a reduction in gene dosage 
and consequently in protein stoichiometry imbalances 68.  It is then clear that the 
effects of aneuploidy are more complex than expected and that aneuploidy can 
drive tumorigenesis, but it does not necessarily do so and it depends on the cell 
context 67.   
Commonly aneuploidy is the result of chromosomal instability characterized by 
gain or loss of entire chromosomes (W-CIN), but the way in which it is gene-
rated is not well clarified. Lots of studies suggest that CIN originates from the al-
teration of genes involved in chromosomal segregation 69. Alteration in the spin-
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dle assembly checkpoint and in the replication of centrosomes have been asso-
ciated to chromosomal instability and aneuploidy in cancer 70,71.   
It has been  now accepted that chromosome biology is largely affected by epi-
genetic marks within chromosomes. The highly degree of compaction, no ac-
cessibility to transcription and recombination machinery as are other chromo-
some regions and  structured nucleosome arrays are all characteristics of he-
terochromatin that depend on epigenetic marks. Although for some time the re-
petitive DNA contained in heterochromatin was considered as “junk”, recent 
evidence indicates that heterochromatin can also play important roles during 
chromosome segregation 72.  
Centromere and epigenetics 
Central to the accurate mechanism of chromosomes segregation during mitosis 
is the assembly of a single site for microtubule attachment, called the kineto-
chore, on each sister chromatid. Kinetochores form the primary interface bet-
ween chromosomes and the mitotic spindle and mediate microtubule-depen-
dent chromosome movements during mitosis. Kinetochores also sense errors in 
chromosome attachment to the mitotic spindle and respond by activating the 
SAC until all chromosomes achieve bipolar spindle attachment. It is the centro-
mere that directs kinetochore assembly, so its structure is fundamental to recruit 
a running kinetochore. The centromere was first named by Walther Flemming 
and described cytologically as  the primary constriction on vertebrate chromo-
somes and was later characterized as a chromosomal region that had a re-
duced recombination frequency 73. All centromeres share the same  chromatin 
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composition characterized by the incorporation of the histone 3 variant centro-
mere protein A (CENP-A) within nucleosomes of centromeric chromatin and the 
AT-rich repeats called alpha-satellite DNA (α-satellite) 73,74. Current experimen-
tal evidences indicate that epigenetic factors modifying centromeric chromatin 
contribute to centromere assembly. CENP-A containing chromatin is usually 
embedded within a large domain of heterochromatin, called pericentric hetero-
chromatin, which is also required for the accurate segregation of chromosomes 
during mitosis. Alteration in centromeric and pericentric chromatin epigenetics 
has been correlated with kinetochore disfunction and chromosomal instability 75-
77.  
DNA methylation and chromosome instability 
Cells with reduced DNA methylation levels appear to be more susceptible to 
undergoing chromosomal loss, gain, or rearrangement, probably because hy-
pomethylation reduces chromosomal stability. Pericentromeric regions are 
characterized by highly repetitive DNA segments termed classical satellites 2 
and 3, which are mainly non-transcribed and highly methylated. These regions 
contain large amounts of methylated constitutive heterochromatin. Somatic cells 
from patients with ICF, a rare genetic disease in which some mutations in the 
Dnmt3b gene have been detected 26, exhibit hypomethylated pericentromeric 
regions associated with chromosomal rearrangements, centromere under-con-
densation, and the formation of micronuclei 78. Apart from ICF syndrome obser-
vation that reveals a connection between DNA demethylation and centromere 
dysfunctions, it was demonstrated a direct correlation between DNA methylation 
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and centromere formation in mammals. The DNA of a functional centromere is 
indeed maintained in an overall hypermethylated state, consistent with the gen-
eral heterochromatic and transcriptionally „„silent‟‟ characteristics of this struc-
ture. Importantly it seems that pockets of hypomethylation within the centromere 
provide the necessary chromatin environment to allow transcription to take 
place without compromising the overall „„heterochromatic‟‟ state and function of 
the centromere 79.  
Pericentromeric regions have also been found hypomethylated in some can-
cers, including hepatocarcinoma, breast, urothelial, and ovarian cancer, and this 
condition was associated with poor prognosis 72. As expected, recently the chro-
mosomal instability observed in colorectal cancer cells has been directly asso-
ciated to genome-wide hypomethylation. This evidence suggests that DNA hy-
pomethylation is likely to induce a cascade effect with direct implications in the 
determination of the tumor progression 60.  
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Research Purpose 
 
Genomic instability is a characteristic of the majority of human tumors and is 
considered a driving force for tumorigenesis. However, when during cancer de-
velopment genome instability arises and what are its molecular basis are ques-
tions still unresolved. Various forms of genome instability have been described 
that are characterized by an increased rate of a number of different genetic alte-
rations 80,81. Most cancers show a form that is called chromosomal instability 
(CIN), which refers to the high rate of numerical and structural chromosome 
changes found in cancer cells compared to normal cells. The presence of CIN 
has also been found in cancer cells grown in vitro. Numerical CIN is characte-
rized by gains and losses of whole chromosomes (aneuploidy) during cell proli-
feration.  Mutations in genes encoding mitotic regulators 82 and in genes control-
ling centrosome numbers and tumor suppressors 83-87 have been suggested as 
molecular defects underlying aneuploidy. However, some of these genes con-
trolling the above processes were not found mutated in aneuploidy cells, in-
stead their expression was reduced suggesting the involvement of possible ep-
igenetic alterations. Thus, epigenetic alterations should be considered as a 
cause of aneuploid cells generation. The regulation of chromatin structure is a 
dynamic and complex process, modulated by epigenetic mechanisms (histone 
modifications and DNA methylation). Malfunctioning of these processes can 
cause gene expression alteration and could compromise important events such 
as chromosome condensation and segregation. Imbalance in cytosine methyla-
tion is a recurrent event in human sporadic cancers. Alteration of methylation 
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patterns includes genome-wide hypomethylation, that could affect chromosome 
condensation, as well localized aberrant hypermethylation of CpG islands, es-
pecially in the promoter region of tumor suppressor genes provoking their si-
lencing. Thus, methylation pattern alterations could be directly implicated in tu-
mor initiation/progression. Hypomethylation and hypermethylation occur at spe-
cific but different sites within the cancer cell genome and can precede malig-
nancy 52. Global genome hypomethylation in breast, ovarian, cervical and brain 
tumors increases with increasing malignancy 52.However, it is still object of inve-
stigation the mechanism(s) that correlates hypomethylation with tumor initiation-
progression. Several hypotheses have been proposed, including chromosomal 
instability induced by hypomethylation of pericentromeric regions 88. Enzymes 
directly involved in DNA methylation are known as DNA methyl-transferases, or 
DNMTs, namely DNMT1, DNMT3a and DNMT3b. DNMT1 differs from the other 
two human DNA methylases, DNMT3a and DNMT3b mainly because it is una-
ble to methylate DNA with both strands unmethylated (de novo methylation) 23. 
DNMT1 is able to restore DNA methylation patterns during cell divisions and it 
has been recently implicated  in genomic stability 23,89. In addition DNMT1 was 
found deregulated in different kind of human tumors suggesting its involvement 
in tumor initiation/progression. However, the DNMT1's role in human cancer 
cells remains controversial. To investigate DNMT1 implication in the generation 
of chromosomal instability (aneuploidy) I evaluated the effects of its depletion by 
RNA interference in primary human fibroblasts (IMR90) and in near diploid tu-
mor cells (HCT116). 
Moreover I wanted to study the effect of DNMT1 overexpression on the methy-
lation of specific gene promoters in normal human cells (IMR90 and MCF10).  
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Results 
Evaluation of DNMT1 post-transcriptional silencing in human cells. 
SiRNAs targeting DNMT1 induce its downregulation in human cells. 
In order to deplete DNMT1 transiently by RNAi in IMR90 and HCT116 cells I 
used a specific siRNA (siDNMT1) 90 targeting a portion of DNMT1 transcript at 
different concentrations: 80nM and 100nM for IMR90 cells, 60nM and 80nM for 
HCT116 and 80nM in MCF10A cells (fig. 14). Microscopy observation of IMR90 
cells transfected with siDNMT1 at 100nM revealed the presence of vacuole-like 
structure within the cytoplasm, likely indicative of cytotoxicity (fig. 14). To avoid 
this side effect the 80nM concentration of siDNMT1 was used for the remaining 
experiments in IMR90 cells.  
MCF10A cells were severely affected by siDNMT1 at 80nM, and at 72 hours 
post transfection the majority of cells were dead and in suspension; the few liv-
ing cells appeared thinner than control cells (fig. 14).  
Real time RT-PCR, using cDNA generated from mRNA extracted 72 hours 
post-transfection from all cellular types, was performed to quantitatively deter-
mine DNMT1 knockdown extent obtained 72 hours after siRNAs transfection. 
The results indicate a significant knockdown (about 80%) using the 80nM con-
centration (fig. 15 A). The experiment was run.  
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To determine whether mRNA decreased levels correlated with Dnmt1 protein 
reduction, protein were extracted  from cells treated with 80nM siRNA targeting 
DNMT1 and from untransfected cells (control).  Western blotting and immuno-
probing revealed a large decrease of  Dnmt1 protein level in IMR90 and only its 
partial reduction  in HCT116 cells (fig. 15 B).  
In order to reduce further Dnmt1 protein in HCT116 cells for other experiments I 
performed two rounds of siDNMT1 transfection separated by 48 hours of reco-
very (HCT-siDNMT1-2t). DNMT1 post-transcriptional silencing was assessed by 
Real Time RT-PCR and western blotting revealed a massive decrease of the 
protein (fig. 15 A, B).  
 
 
 
 
 
Figure 14. Morphology of IMR90, HCT116 and MCF10A cells after 24 hours post-transfection of 
siDNMT1 at concentrations of different concentrations (80 and 100nM for IMR90; 60 and 80nM 
for HCT116; 80nM for MCF10A). 
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Figure 15. A) Real Time RT-PCR analysis of IMR90, HCT116 and MCF10A cells showing de-
crease of DNMT1 transcriptional reduction after 72 hours from transfection of  two different con-
centration of siRNAs targeting DNMT1, and of HCT116 cells after a double round with siDNMT1 
80nM (HCT siDNMT1 2t). B) Western Blot analysis showing the reduction of Dnmt1 protein in 
both IMR90 and HCT116 cells treated with siDNMT1 80nM and in HCT116 siDNMT1 2t, con-
sistent with Real Time RT-PCR results. 
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Transient DNMT1 downregulation induces aneuploidy, alterations of 
centromeric structure and micronuclei formation.  
To ascertain if epigenetic alterations might be implicated in the generation of 
chromosomal instability, I investigated if transient DNMT1 post-transcriptional 
silencing could induce aneuploidy in normal diploid cells. To this aim I did cyto-
genetics analyses in IMR90 and HCT116 cells treated for 72 hours with 
siDNMT1 or left untreated. The cytogenetics analysis showed that DNMT1 post-
transcriptional silencing induced a high percentage of aneuploid cells in both 
cell strains. However, very few metaphases were observed in IMR90 siDNMT1 
cells (mitotic index 0,3%), despite the treatment with colcemid for 8 hours, and 
the majority of IMR90 siDNMT1 metaphases were hyperdiploid (78%). On the 
contrary mitotic index of HCT siDNMT1 cells was not compromised and mitotic 
cells showed increase of hypodiploid cells (62%) (fig. 16 A, B). I also found 
anomalies of centromeric and pericentromeric region that seemed to be less 
stained with Giemsa in respect to the one of control cell, suggesting the pre-
sence of decondensed chromatin at that level (fig. 16 C). 
 DAPI staining of interphase nuclei showed high percentage of IMR90 siDNMT1 
cells with micronuclei (37,6% of observed nuclei) (fig. 16 D).  
I checked the number of centrosomes in order to exclude the involvement of 
centrosomes amplification in the generation of aneuploid cells, one of the 
known causes of aneuploidy induction in normal cells. Immunofluorescence mi-
croscopy analysis against -tubulin, the most important component of centro-
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somes showed absence of supernumerary  centrosomes (fig. 16 D), indicating 
that the observed aneuploidy was not induced by centrosomes amplification. 
 
Figure 16. A) Histogram showing percentages of both aneuploid and diploid metaphases. Both 
IMR90 and HCT116 cells acquired aneuploidy after 72 hours from siDNMT1 transfection. B) 
Pictures of metaphase spreads of both untransfected and siDNMT1 transfected IMR90 and 
HCT116 cells. On the left panels are example of IMR90 and HCT116 diploid metaphases (2N); 
on the right panels example of IMR90-siDNMT1  hyperdiploid metaphase and HCT116 
siDNMT1 hypodiploid metaphase. C) Pictures of metaphase spreads of IMR90 wt and siDNMT1 
cells. IMR90-siDNMT1 cells show alterations in chromosomal pericentromeric region where 
chromatin seemed to be decondensed in comparison to control (see inserts). D) IMR90-
siDNMT1 nuclei stained with DAPI and detected with anti- tubulin antibody (green spots) show-
ing the presence of morphological alterations, micronuclei and centrosomes.  
A B 
C D 
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Transient DNMT1 downregulation provokes cell growth inhibition.  
It is conceivable that DNMT1 depletion, causing defects in DNA methylation, will 
be sensed by the cell as a stress signal eliciting a cell cycle response (ar-
rest/delay). Indeed, early effects (72 hours) of DNMT1 post-transcriptional si-
lencing resulted in slowing down cell proliferation in both IMR90 siDNMT1 and 
HCT siDNMT1, as I just observed by their cellular morphology and by the cel-
lular density/dish that was lower than the one showed by control cells (fig. 17 
A). By counting cell numbers every 24 hours from siRNA transfection I found 
that IMR90-siDNMT1 cell numbers did not vary during the first 72 hours of si-
lencing. However, these cells resumed proliferation and at 144 hours post-
transfection the cellular density/dish was almost 100%. On the contrary, HCT-
siDNMT1 cells duplicate once in 72 hours after transfection of siRNAs targeting 
DNMT1 (fig. 17 A). These observations suggest that DNMT1 depletion caused 
a transient cell cycle arrest in IMR90 cells (72h) and slowed-down proliferation 
in HCT116 cells.  
To address this further I did cytofluorimetry analysis of IMR90-siDNMT1 and 
HCT116-siDNMT1 cells at 72 hours post-transfection to compare them with 
control cells (untreated/asynchronous). Cytofluorimetry analysis showed a large 
decrease in the number of S-phase BrdU positive IMR90-siDNMT1 cells and 
accumulation of the cells in the G1-phase indicative  of a G1 arrest. On the con-
trary, HCT116-siDNMT1 cells did not arrest in G1 but they accumulated in S 
phase delaying the G2/M phase entry (fig. 17 B).  
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These results suggest a different response to DNMT1 downregulation of normal 
versus tumor cells. Moreover the cell cycle block in IMR90 cells was transient 
because cells re-entered cell cycle after 144 hours from transfection. 
Figure 17. A) Pictures and histogram showing the effects on proliferation of siRNAs targeting 
DNMT1 at 72 and 144 hours in IMR90 and HCT116 cells. Human fibroblasts slowed down pro-
liferation in comparison to control cells at 72 h, however they resumed proliferation at 144h. 
HCT116 cells growth was less affected by DNMT1 silencing. B) Cytofluorimetric profiles of 
IMR90 and HCT116 cells pulsed with BrdU for 1h, and then stained with anti-BrdU antibody 
FITC-conjugated and propidium iodide. After DNMT1 silencing both IMR90 and HCT116 cells 
show delayed S-phase entry. In particular IMR90 arrested in G1/S.  
In order to investigate further on the cell cycle arrest induced in IMR90 
siDNMT1 cells and understand at what time cells restart to proliferated between 
the 72 and 144 hours, I performed a cytofluorimetry analysis staining cell DNA 
with propidium iodide at 72, 84 and 96 hours post transfection. These experi-
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ments showed that cells exit G1 phase between 84 and 96 hours post transfec-
tion, since the number of G1 cells is slightly reduced.  
These results suggest that the cell cycle arrest induced by DNMT1 depletion is 
not transient.   
 
 
 
 
 
 
Figure 18. Cytofluorimetric profiles of IMR90 wt and DNMT1 silenced for 72, 84 and 96 hours 
stained with propidium iodide (PI). IMR90 cells restart to enter S phase between 84 and 96 
hours post siDNMT1 transfection. 
Dnmt1 depletion induces a global DNA demethylation.  
One potential role of the G1-arrest triggered by Dnmt1 depletion is to protect the 
epigenome from global loss of DNA methylation. To address this question I in-
vestigate if DNMT1 silencing causes DNA demethylation.  
Cells type G1 S G2/M 
IMR90 wt 68% 15% 17% 
IMR90 siDNMT1 72h 79,60% 9,80% 10,60% 
IMR90 siDNMT1 84h 80% 10,50% 9,50% 
IMR90 siDNMT1 96h 76,30% 12,90% 10,80% 
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I used the tumor HCT116 cell line for the study of DNA methylation. Using anti-
5-methylcytosine antibody I compared the state of methylation of HCT116 cells 
treated for 72 hours with siDNMT1 and not treated. HCT116 cells treated with 
siDNMT1 and its control were stained with the “capture antibody” and subse-
quently the “detection antibody” (secondary antibody) and were quantified 
through an ELISA-like reaction. HCT116 siDNMT1 cells resulted demethylated 
(1,2% of methylated DNA vs 5,65% of control) (table 1).  
 
Table 1. Level of global DNA methylation in HCT116-wt and HCT116-siDNMT1 cells. DNA ex-
tracted from HCT116-siDNMT1 cells appeared demethylated in comparison to that extracted 
from HCT116 cells. 
The G1 arrest following DNMT1 silencing in IMR90 fibroblasts possibly protects 
cells from genome wide loss of methylation.  
Next, I addressed the question of whether this difference in the kinetics of global 
DNA methylation between siDNMT1 treated and untreated cells is also ob-
served when specific genes are examined. I focused on the hypermethylated 
promoter of CHFR gene in HCT116 cells 91 and I determined the pattern of its 
methylation after siDNMT1 treatment. The methylation pattern was studied by 
Methylation Specific PCR (MSP). This technique consists in a previous treat-
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ment of genomic DNA with sodium bisulfite that change the unmethylated cyto-
sines in uracyl that in turn becomes a thymine inducing point mutations in DNA 
sequence. By using two different sets of primers, designed on the methylated 
and unmethylated sequence, it is possible to distinguish the methylation status 
of a particular sequence. First, I tested the efficiency and specificity of the tech-
nique using two different cell lines that are known to have the CHFR gene pro-
moter hypermethylated (HCT116) or unmethylated (SW480) in both strands of 
DNA 91. MSP revealed the specificity of both sets of primers since they allow the 
amplification only of the sequence for CHFR unmethylated or methylated pro-
moter (fig. 19). Moreover, to be sure that CHFR promoter could undergo deme-
thylation I performed some treatments with 5-aza-deoxycitydine, a demethylat-
ing agent, used at different concentrations (1, 2 and 5µM) (fig. 19).  
The result of this analysis showed no significative difference of methylation 
state between HCT siDNMT1 and the untreated cells since CHFR promoter re-
mained fully methylated 72 hours after siDNMT1 transfection (fig. 19).  
I supposed that the residual protein present in HCT116 cells treated with 
siDNMT1 for 72 hours might be the cause of the maintenance of CHFR promo-
ter methylation. In order to obtain more silencing of Dnmt1 protein in HCT116 
cells, I performed two rounds of 80nM siDNMT1 transfection separated by 48 
hours of rest (HCT116 siDNMT1(2t)).  Unexpectedly I did not observe demethy-
lation on CHFR gene promoter (fig. 19).  
My results excluded the possibility that CHFR promoter methylation depends 
only on Dnmt1 protein activity. Thus I hypothesized that this methylation occurs 
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in collaboration with others DNA methyl-transferases, such as DNMT3b, even if 
Real Time RT-PCR did not reveal any increase of its transcription. 
  
Figure 19. Methylation Specific PCR (MSP) amplification shows methylation status of CHFR 
gene promoter in human cell lines. SW480 cells were used as a positive control of unmethy-
lated status of the CHFR gene promoter. HCT116 cells treated with one and two rounds (2t) of 
siDNMT1 did not show any modification in methylation of CHFR gene promoter. HCT116 cells 
were treated with 5-aza-deoxycitydine (DAC) (1, 2, 5µM) for 72 hours continuatively or by ad-
ding fresh DAC at 36 hours in order to induce CHFR gene promoter demethylation. 
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IMR90 cells sense early DNMT1 decrease by activating TP53 and 
p21waf1.  
I reasoned that DNMT1 downregulation might be targeting a pathway similar to 
that responding to DNA replication stress, leading to inhibition of firing origins of 
DNA replication and arrest of DNA synthesis. I therefore examined the effect of 
DNMT1 silencing on the expression of the most important genes involved in G1 
(p21waf1 and TP53) and G2/M (BubR1, MAD2 and AuroraA) cell cycle check-
points.  
Real time RT-PCR revealed a strong increase of p21waf1 transcript in IMR90 
siDNMT1 cells in comparison with control cells, and a slight increase in TP53 
transcript (fig. 20 A). These results were accompanied by correspondent protein 
increase assessed by Western blot analysis. Moreover, I noticed that after 144 
hours from single DNMT1 silencing, when IMR90 cells restart to proliferate, 
TP53 protein level is reduced in respect of cells at 72 hours (fig. 20 B, C).  
On the contrary I did not observe increase of p21waf1 and TP53 in proliferating 
HCT116 siDNMT1 cells (fig. 20 A, B).  
As a confirmation of the G1 arrest of IMR90 siDNMT1, transcriptional levels of 
BubR1 and Aurora A, involved in mitosis, were very low (fig. 20 A). On the con-
trary MAD2 levels were higher than in control cells (fig. 20 A), even if MAD2 is 
involved in mitosis too. This result could be a side effect of DNMT1 silencing 
probably correlated with MAD2 gene promoter demethylation. 
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Figure 20. A) Real time RT-PCR and (B,C) WB  analysis revealed a strong increase of p21
waf1
 
and TTP53 proteins level in IMR9O cells and not in HCT116 cells. At 144 hours from siDNMT1 
transfection TTP53 level came back to basal level. Cells treated with adriamicyn to induce DNA 
damage were used to assess the functionality of  the TTP53 pathway. 
These results agreed with TP53 involvement in the cell cycle arrest triggered by 
DNMT1 downregulation.  
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IMR90 cells sense Dnmt1 decrease and activates a TP53-controlled 
pathway. 
To understand if TP53 is really involved in cell cycle arrest triggered by DNMT1 
downregulation, I performed a double siRNAs transfection with siDNMT1 and 
siTP53 together in IMR90 cells. Real Time RT-PCR and Western blot analysis 
confirmed DNMT1 and TP53 decrease in respect to control cells (fig. 21 A, B). 
72 hours post-transfection I found a number of cells in culture comparable to 
control, suggesting an almost unchanged cell proliferation (fig. 21 C). Biparame-
tric cytofluorimetric assay showed also that siDNMT1/siTP53 cells underwent a 
normal cell cycle recovering from the G1 arrest of IMR90 siDNMT1 cells (fig. 21 
C).  
Moreover, Western blot analysis showed that in double silenced cells p21 waf1 is 
not incremented (fig. 21 B). 
These findings suggest that TP53 reduction allowed cell cycle progression of 
Dnmt1 depleted IMR90 cells bypassing the G1 arrest and in turn that TP53 is 
involved in the pathway that induced the G1 arrest in IMR90 siDNMT1 cells. 
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Figure 21. A) Real time RT-PCR and (B) WB detection of TTP53 and Dnmt1 levels in IMR90-
siDNMT1/TP53 cells and in IMR90-wt cells. C) Top panels: IMR90-wt and MR90-
siDNMT1/TP53 cells pictures at 72 hours post-transfection showing that the cell density/dish in 
IMR90-siDNMT1/TP53 cells is comparable to that of IMR90-wt cells. Bottom panels: cytofluori-
metric profiles showing no significative differences in cell cycle distribution of wt and IMR90-
siDNMT1/TP53 cells. 
DNMT1 depletion does not induce DNA damage.  
In order to understand the pathway that activates/stabilizes TP53 after DNMT1 
depletion in IMR90, I evaluated the activation of those pathways that are known 
to induce a G1 arrest involving TP53 (fig. 22).  
To this aim I checked if DNMT1 depletion could induce DNA damage. The fact 
that HCT116 respond to adriamicyn, a drug that induce DNA double strand 
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breaks, and not to DNMT1 deregulation activating TP53 (fig. 20B) was already 
a first suggestion that DNMT1 downregulation did not induce DNA damage.  
Figure 22. Scheme of the pathways activating TP53. Cellular stress (oncogenes activation) in-
duces p14ARF, which sequesters MDM2. In addition, DNA damage and chemotherapeutics ac-
tivate ATM and ATR, which phosphorylate the amino terminus of TP53 to prevent MDM2 bind-
ing, and the carboxyl terminus of TP53 respectively to increase sequence-specific DNA binding. 
These events increase TP53 levels and activate the transcription of TP53 target genes
92
. 
However, in order to exclude the induction of DNA damage I monitored the 
amount of phosphorylated H2A.X protein (H2AX) by immunofluorescence mi-
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croscopy. Phosphorylated H2A.X is a modified histone that accumulates at 
double-stranded breaks and functions to recruit DNA repair protein. I observed 
a small difference of H2AX signals between control (IMR90 wt and HCT116 wt) 
and  transfected cells (IMR90 siDNMT1 and HCT siDNMT1). On the contrary, 
cells treated with adriamycin were positive to H2A.X antibody (fig. 23).  
Figure 23. Immunofluorescence analysis against H2A.X revealed that DNMT1 silencing did not 
induce H2A.X positive foci formation in both IMR90 and HCT116 cells. Cells treated with 
adriamycin were used as a positive control. 
Moreover, I evaluated also the possible transcriptional activation of DNA repair 
proteins (RAD51L1, RAD51L2, RAD51L3) by Real time RT-PCR, but I did not 
observe overexpression of these genes (fig. 24). 
Altogether these results showed that the putative pathway mediated by TP53 
and triggered by DNMT1 downregulation is not induced by DNA damage. 
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Figure 24. Real time RT- PCR showing underexpression of RAD51L1-3 in IMR90 siDNMT1 
cells. 
Double silencing of p14ARF and DNMT1 abrogates G1 arrest in 
IMR90 cells.  
In order to investigate on the pathway that activates TP53 in IMR90 siDNMT1 
cells triggering the G1 arrest, I checked also the involvement of p14ARF, that is 
known to stabilize TP53 sequestering MDM2 (fig. 22). First, I looked at its tran-
scriptional levels by Real time RT-PCR, but I did not found significative diffe-
rences in respect to untreated cells. 
P14ARF expression remains almost unchanged also at 144 hours post 
siDNMT1 transfection, but it is underexpressed in siDNMT1/TP53 double si-
lenced cells (fig. 25).  
To investigate further on p14ARF potential involvement in TP53 activation after 
DNMT1 depletion I performed a double siRNAs transfection with siDNMT1 and 
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sip14ARF in IMR90 cells. 72 hours post-transfection the number of cells in cul-
ture 
Figure 25. Real time RT-PCR showing the relative levels of p14ARF transcripts in wt, siDNMT1, 
siDNMT1 144 hours and siDNMT1/TP53 IMR90 cells. P14ARF levels do not changed after 
DNMT1 silencing, but are reduced in siDNMT1/TP53 cells. 
was comparable to control, suggesting an almost unchanged cell proliferation 
(fig. 26). 
Figure 26. IMR90-wt and MR90-siDNMT1/p14ARFARF cells pictures at 72 hours post-
transfection showing that the cell density/dish in IMR90-siDNMT1/p14ARFARF cells is compa-
rable to that of IMR90-wt cells. 
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DNMT1 post-transcriptional silencing induces pRb reduction  
The retinoblastoma protein, pRb, is a tumor suppressor protein belonging to the 
pocket protein family that is dysfunctional in many types of cancer. It binds and 
inhibits transcription factors of the E2F family that can push a cell into S phase. 
As long as E2F is inactivated, the cell remains stalled in the G1 phase.  
To investigate further on the G1 arrest induced by DNMT1 downregulation I 
looked at pRb expression after DNMT1 downregulation. Real time RT-PCR and 
Western blot analyses showed pRb decrease in IMR90 cells treated for 72 
hours with siRNA targeting DNMT1. PRb protein levels were restored at 144h 
post-transfection (fig. 27 A, B). Accordingly to these results there was also a 
decrease of CDKN3 transcript after DNMT1 post-transcriptional silencing (fig. 
27 A). CDKN3 inhibits CDK2/cyclinE complex contributing to not phosphorylate 
pRb and consequently to deactivate E2F. Moreover, in DNMT1/TP53 silenced  
Figure 27. A) Real time RT-PCR showing the relative transcriptional levels of pRb and CDKN3 
in wt, siDNMT1, siDNMT1 144 hours and siDNMT1/TP53 IMR90 cells. B) Western blot analysis 
showing protein levels of pRb in IMR90 wt, siDNMT1 at 72 and 144 hours and siDNMT1/TP53. 
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cells pRb transcriptional levels were reduced in respect of untreated cells, but 
were higher than in siDNMT1 cells (fig. 27 A). Western blot analysis showed 
that pRb protein levels were restored when TP53 is silenced with DNMT1 (fig. 
27 B).   
Double silencing of DNMT1 and TP53 induced aneuploidy in IMR90 
cells 
My results are consistent with the hypothesis of TP53 involvement in the G1 ar-
rest induced by DNMT1 depletion in IMR90. In order to understand if the abro-
gation of this cell cycle arrest alters cellular ploidy I performed a cytogenetics 
analysis in siDNMT1/TP53 IMR90 cells. The analysis showed that the number 
of IMR90-siDNMT1/TP53 metaphases was similar to that of untransfected 
IMR90 cells (mitotic index 3%) and that the majority of them (70%)  were hypo-
diploid (fig. 28) like  the HCT-siDNMT1 cells that did not arrest in G1. 
Figure 28. Histogram showing percentages of both aneuploid and diploid metaphases. IMR90 
siDNMT1/TP53 cells acquired hypodiploidy. 
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Evaluation of the effects of DNMT1 overexpression in human cells. 
In order to investigate on the long term consequences of DNA hypermethylation 
in normal cells I studied the effects of DNMT1 overexpression in IMR90 and 
MCF10A cells.  
Generation of pRB stably depleted MCF10A cells  
Previous experiments have highlighted that pRb depletion induce DNMT1 over-
expression in human cells (IMR90 and HCT116). So the first approach to obtain 
DNMT1 overexpression was indirect by inducing pRb stable post-transcriptional 
silencing in MCF10A cells. In order to  silence pRb I used retroviral particles 
containing MSCV-LMP vector (LMP microRNA adapted vector) 93 (fig. 29 A). In 
this vector is cloned a synthetic microRNA (mir670) that once processed origi-
nates antisense RNA directed against a portion of the pRb transcript. Pairing 
between miRNA and mRNA strands provokes mRNA translation inhibition or 
degradation. In this way MSCV-LMP induces a stable post-transcriptional si-
lencing of pRb. Retroviral particles were produced by packaging cells (Phoenix) 
transfected with the MSCV-LMP vector. Transfection efficiency was assessed 
by fluorescence microscopy since the vector contains GFP (Green Fluores-
cence Protein) cDNA (fig. 29 B). At 48 hours post transfection culture medium 
containing retroviral particles was collected, filtered and used to infect MCF10A 
cells. At 72 hours post infection cells containing retroviral vector were selected 
in puromycin for a week. Real Time RT-PCR  confirmed pRb reduction (90%) 
(fig. 29 C). Unexpectedly pRb silencing gradually inhibited MCF10A cell growth 
then inducing a complete cell cycle arrest, assessed by cytofluorimetry (fig. 29 
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D). In order to verify DNMT1 overexpression I did a real time RT-PCR reaction, 
that showed, instead, DNMT1 downregulation. In addition to DNMT also others 
genes such as DNMT3b, MAD2 and Aurora A were downregulated after pRb si-
lencing (fig. 29 C). Probably pRb post-transcriptional silencing induced a strong 
cellular stress in these cells leading them to metabolic and growth arrest. For 
these reasons it was not possible to investigate further these cells. 
Figure 29. A) Scheme of MSCV-LMP vector containing mir670. B) Pictures showing Phoenix 
cells transfected with MSCV-LMP mir670 vector. GFP fluorescence indicates cells that received 
the plasmid. C) Real time RT-PCR showing transcript levels of Rb, DNMT1, DNMT3b, Aurora A 
and MAD2 in MCF10A mir670 cells. D) Cytofluorimetric profiles and time course of MCF10A 
mir670 cells compared to that of untreated cells. 
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Generation of IMR90 cells overexpressing DNMT1   
I used a second strategy to obtain DNMT1 overexpression by transfecting a 
vector (PCMV HMT) harboring DNMT1 cDNA cloned 94 (fig. 30 A)in IMR90 
cells. I did several experiments to transfect this vector in IMR90 cells and every 
time cells selected in G418 for a week died immediately (fig. 30 B). I supposed 
that DNMT1 overexpression was lethal for IMR90 cells. 
 
Figure 30. A) Scheme of PCMV vector. B) Pictures showing IMR90 cells transfected with 
PCMV-HMT vector in respect to wt cells.    
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Discussion 
 
It is known that DNA methylation, histone methylation and deacetylation com-
bine to bring about DNA hypercondensation typical of centromeric and pericen-
tromeric chromatin 95,96. Imbalance in cytosine methylation at CpG islands and 
deregulation of DNA methyl-transferases, in particular DNMT1, are recurrent in 
human sporadic cancers 46-49 and it seems that they could be involved in the 
acquisition of chromosomal instability 88 by inducing chromatin decondensation 
at the centromere region of chromosome. This in turn could result in altered ki-
netochore formation/assembling and chromosomes missegregation. The aim of 
my work has been to understand if DNMT1 transient depletion by RNA interfer-
ence could be implicated in the generation of aneuploidy by altering DNA me-
thylation patterns.  
By using two different cell strains, human primary fibroblasts (IMR90)  and sta-
ble near-diploid tumor cells (HCT116), I determined that Dnmt1 transient deple-
tion had different outcomes related to the genetic context of the cell. The first 
observed consequence of DNMT1 post-transcriptional silencing was the arrest 
of cellular proliferation in IMR90 human fibroblasts. On the contrary, only a 
slight decrease of cell proliferation was observed in HCT116 cells. This differ-
ence was confirmed by FACSscan analysis showing IMR90 cells arrested in the 
G1 phase of the cell cycle and HCT116 cells lightly accumulated in S phase. As 
a consequence of the proliferation arrest mediated by Dnmt1 transient depletion 
IMR90 fibroblasts showed very few mitotic cells (mitotic index 0,3%). Untrans-
formed cells activated a G1/S checkpoint preventing S-phase entry, while tumor 
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cells delayed cell cycle progression extending S-phase duration when DNMT1 
was reduced. 
DNMT1 usually localizes at replication foci because of its interaction with the 
proliferating cell nuclear antigen, PCNA 41,97. It is possible that low levels of 
DNMT1 lead to a delayed and difficult S phase progression in tumor cells. On 
the contrary its severe depletion is perceived before entering S phase in order 
to block cell cycle immediately (G1) in normal cells. Propidium iodide staining 
revealed also that IMR90 siDNMT1 cells can already exit G1 in less than 24 
hours after the arrest, suggesting that the arrest is relieved as soon as DNMT1 
is re-expressed .   
DNMT1 depletion could also be sensed by cells as a danger signal that induce 
them to arrest in order to prevent the effect of global DNA demethylation. In 
fact, using anti 5-methylcytosine antibody to check DNA methylation status, I 
noticed DNA demethylation in HCT siDNMT1 cells that do not arrest. Unexpect-
edly, I did not observe any modification of methylation status of CHFR gene 
promoter found to be hypermethylated after DNMT1 post transcriptional silenc-
ing in HCT116 cells, suggesting that DNMT1 is not the only methyl-transferase 
involved in its hypermethylation status 98. My results are consistent with the no-
tion that the lack of DNA replication following DNMT1 depletion in normal cells 
prevents the generation of daughter cells with hypomethylated DNA. Moreover, 
I noticed that in a genetic contest of cancer cells where DNMT1 is overex-
pressed cells do not sense its scarce and/or strong decrease as a danger and 
do not arrest but have only a delayed S phase. 
The cellular  checkpoint  triggered by Dnmt1 depletion seems mediated by 
TP53 activation because of its overexpression/stabilization in arrested IMR90 
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cells. TP53 involvement in this response was further directly suggested by the 
findings that DNMT1 and TP53 double silenced IMR90 cells did not arrest any-
more. Moreover, the observation that IMR90 cells restarted to proliferate at 144 
hours from siDNMT1 transfection and that TP53 amount returned to basal lev-
els, are additional evidences of the existence of a checkpoint TP53 controlled 
that responds to Dnmt1 lack.  
However, this checkpoint seems different from the classic TP53 pathway acti-
vated by DNA damage. In fact, HCT116 cells, that responded correctly to the 
presence of DNA damage - as showed by adriamycin treatment that induced 
double strand breaks - by increasing the levels of TP53 and of its effector p21 
waf1, were unable to halt cellular proliferation in response to transient Dnmt1 de-
pletion. In addition, it was not possible to find DNA damage in IMR90 siDNMT1 
cells, at least as revealed by H2A.X foci, even if DNMT1 depletion was previ-
ously associated with H2A.X foci in T24 cells 99. I hypothesize that a specific 
intermediate activating TP53 in response to Dnmt1 depletion in IMR90 cells is 
lacking in HCT116 cells, thus allowing cell cycle progression of these cells.  
Investigating the other classic TP53 pathway that is induced by p14ARF, I dis-
covered that, unless p14ARF transcript level remained almost unchanged in 
DNMT1 depleted in respect to control cells, it decreased in double DNMT1 and 
TP53 silenced cells that were not arrested. In addition, double DNMT1 and 
p14ARF silenced IMR90 cells seem to proliferate normally, reinforcing the idea 
of the p14ARF involvement in the G1 arrest. The fact  that HCT116 cells do not 
express p14ARF, because one allele is mutated and the other have the pro-
moter region hypermethylated 100, could explain the lack of G1 arrest in these 
cells. These results suggest that p14ARF could be the intermediate that acti-
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vates TP53 triggering the G1 arrest in IMR90 cells and its lack allow cell cycle 
progression of DNMT1 depleted HCT116 cells.  
Generally, in a G1 arrest induced by p21 waf1 activation, p21waf1 inhibits pRb 
hyperphosphorylation by Cdk/cyclin complexes. In this way pRb does not re-
lease E2F and S-phase genes are not induced. The observed pRb and CDKN3 
decrease was unexpected in a contest of p21waf1 and TP53 overexpression and 
G1 arrest. However, it has been reported that cell cycle arrest with p21waf1 over-
expression is associated with pRb decrease 101. Moreover, pRb and CDKN3 
decrease seems to depend on cell cycle arrest since pRb levels are restored 
when the putative checkpoint is silenced as observed after 144 hours post 
siDNMT1 transfection and in siDNMT1/siTP53 cells. These results suggest the 
existence of a negative feedback which gets cells ready for reentering cell cycle 
after the arrest (the arrest is transient).  
In order to understand DNMT1 correlation with aneuploidy, I checked chromo-
some numbers in IMR90 and HCT116 cells after DNMT1 silencing. Since 
IMR90 cells were arrested I could analyse only few metaphase cells (mitotic in-
dex 0,3%) that were mainly hyperdiploid. On the other hand mitotic index of 
HCT116 cells was not compromised by DNMT1 silencing and I observed a high 
percentage of hypodiploid cells. Probably, the fact that IMR90 cells promptly ar-
rest after DNMT1 silencing prevents the acquisition of an aneuploid phenotype, 
even if cells that escape the block do. On the contrary, HCT116 cells acquired 
aneuploid phenotype because they did not arrest in G1.  
Moreover, the finding that the centromere of mitotic IMR90 siDNMT1 cells 
seems to be les stained suggest the presence of decondensed chromatin 
around centromeric and pericentromeric region. These alterations could be the 
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cause of aneuploidy generation. Altered chromatin structure around the centro-
mere could compromise the correct kinetochore assembly and/or the correct 
microtubules attachment to chromosomes. These could result in incorrect seg-
regation of sister chromatids 76,77. Since I noticed that if cells succeed in en-
tering S phase and continue to proliferate, even in DNMT1 absence (HCT 
siDNMT1cells), their genome is demethylated, demethylation could involve 
pericentromeric chromatin leading to decondensation. This, in turn, could affect 
the correct chromosome segregation generating aneuploidy.  
As a confirmation of this hypothesis, an increased number of IMR90 aneuploidy 
cells was seen only after unscheduled G1/S progression induced by the tran-
sient TP53 silencing when DNMT1 is depleted (DNA demethylation).  
In this way one potential role for the TP53 induced G1 arrest triggered by 
DNMT1 reduction could be not only to protect the epigenome from global loss of 
DNA methylation pattern, but also to prevent the subsequent aneuploidy.  
Finally, these findings suggest that primary human cells perceive the Dnmt1 ab-
sence that might lead to hypomethylation, profoundly altering the epigenome, 
as a stress signal and thus activate a TP53 controlled pathway, probably in-
duced by p14ARF, that in turn induces G1 arrest. When this pathway is not 
working as in tumor cells or it is abrogated by silencing TP53, cells progress in-
correctly in the cell cycle with altered DNA methylation pattern (hypomethyla-
tion) that might affects also the right chromosomal segregation thus resulting in 
aneuploidy (fig. 31). 
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Figure 31. Speculative model of a putative pathway induced by DNMT1 depletion. Dnmt1 deple-
tion is perceived by a putative “sensor” factor that activates a pathway p14ARF/TP53 controlled 
triggering G1 arrest in normal cells. Moreover, the putative sensor factor induces pRb and 
CDKN3 decrease in order to assure a prompt relief from cell cycle arrest. If TP53 or p14ARF 
are absent or not working properly, cells are unable to sense Dnmt1 depletion and thus 
progress in the cell cycle incorrectly with wrong DNA methylation patterns triggering aneuploidy. 
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Material and methods 
 
Cells and cell culture 
Human primary fibroblasts (IMR90 passage 12, ATCC) were cultured in EMEM 
supplemented with: 10% FBS (GIBCO, Invitrogen), 100units/ml penicillin and 
0,1 mg/ml streptomycin (Euroclone Ltd UK), 1% NEAA (GIBCO); the human co-
lon cancer cell line HCT116 were cultured in DMEM supplemented with: 10% 
FBS, 100units/ml penicillin and 0,1 mg/ml streptomycin; MCF10A cells (a gen-
erous gift of Prof. G. Stassi, University of Palermo) were cultured in DMEM/F12 
(GIBCO, Invitrogen) supplemented with: 10% FBS, 100units/ml penicillin and 
0,1 mg/ml streptomycin, 0,5mg/ml Hydrocortisone, 10mg/ml Insulin, 20ng/ml 
EGF (SIGMA). Cells were cultured in a humidified atmosphere of 4% CO2 in air 
at 37°C. 
 
RNA interference 
For siRNAs transfection 1,5x105 IMR90 cells and 2,5x105 HCT116 cells were 
plated in 6-well dishes and incubated at 37°C. Specific siRNAs duplex were 
mixed with Lipofectamine2000 Reagent (Invitrogen), according to manufac-
turer‟s recommendation and added to the cells. After 6 hours at 37°C, the trans-
fection medium was replaced with fresh medium. To silence genes of interest 
post-transcriptionally, cells were transfected with siRNAs targeting DNMT1 
(siDNMT1: 5‟- AUU ACG UAA AGA AGA AUU A dTdT-3‟) 90 at final concentra-
tions of 60, 80 and 100nM, siRNAs targeting TP53 (si TP53: 5‟-GCA UGA ACC 
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GGA GGC CCC AUtt-3‟) 102 and p14ARF (sip14: 5'-GAA GAU CAG GUC AUG 
AUG Att-3') at a final concentration of 60nM. All siRNAs were synthesized by 
Eurofins-MWG (Germany).  
The day of transfection the siRNA and the transfection reagent (Lipofectamine 
2000, Invitrogen) were diluted separately in Opti-MEM (Invitrogen) mixed gently 
and then incubated for 5 minutes at room temperature. After incubation the 
siRNA and Lipofectamine 2000 (Invitrogen) were mixed gently, allowed to sit 20 
minutes at room temperature to allow complex formation, and added to the 
plates with 2 ml of medium for 72 hours. 
 
Stable pRb post transcriptional silencing in MCF10A cells. 
For MSCV-LMP mir670 transfection 3x106 packaging cells (Phoenix) were 
plated in 100mm dishes and incubated at 37°C. 8µg of plasmid DNA was mixed 
with Lipofectamine2000 Reagent (Invitrogen), according to manufacturer‟s re-
commendation and added to the cells. During 72 hours retroviral particles were 
produced by cells and released in the medium. At 72 hour the medium was fil-
tered and added to MCF10A cells with 4µg/ml Polybrene. After 5 hours from in-
fection the medium was changed and plates incubated at 37°C. At 72 hours 
cells were selected with puromicyn 1µg/ml for a week. 
 
PCMV-HMT transfection in IMR90 cells. 
For PCVM-HMT plasmid (a gentle gift from Paula Vertino, Emory University, At-
lanta) transfection 5x105 IMR90 cells were plated in 100mm dishes and incu-
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bated at 37°C. 8µg of plasmid DNA were mixed with Lipofectamine2000 Re-
agent (Invitrogen), according to manufacturer‟s recommendation and added to 
the cells. At 72 hour cells were selected with G418 100µg/ml for a week. 
Real time RT-PCR 
Primers to be used in real time RT-PCR experiments were designed with Primer 
Express software (Applied Biosystems) choosing amplicons of approximately 
70-100 bp. The selected sequences were tested against public databases 
(BLAST) to confirm the identity of the genes. Total RNA was extracted from 
cells by using the RNAeasy mini kit (GE) or the “All prep DNA/RNA kit” (Qiagen) 
according to the manufacture‟s instruction. RNA was reverse-transcribed in a fi-
nal volume of 100 µL using the High Capacity c-DNA Archive kit (Applied Bio-
systems) for 10 minutes at 25° C and 2 hours at 37°C. For each sample 2 µL of 
cDNA, corresponding to 100 ng of reverse transcribed RNA, was analyzed by 
Real time RT-PCR (95°C for 15 sec, 60°C for 60 sec repeated for 40 cycles), in 
quadruplicate, using the ABI PRISM 7300 instrument (Applied Biosystems). 
Real Time RT-PCR was done in a final volume of 20µl comprising 1x Master 
Mix SYBR Green (Applied Biosystems) and 0,3µM of forward and reverse pri-
mers for: DNMT1 (Fwr: 5‟-GCACCTCATTTGCCGAATACA-3‟; Rev: 5‟-
TCTCCTGCATCAGCCCAAATA-3‟), TP53 (Frw: 5‟-
TTCGACATAGTGTGGTGGTGC-3‟; Rev: 5‟-AGTCAGAGCCAACCTCAGGC-
3‟), p21waf1 (Frw: 5‟-CTGGAGACTCTCAGGGTCGA-3‟, Rev: 5‟-
CGGATTAGGGCTTCCTCTTG-3‟), GAPDH (Frw: 5‟-
CTCATGACCACAGTCCATGCC-3‟, Rev: 5‟- GCCATCCACAGTCTTCTGGGT-
3‟), pRb (Frw: 5‟-GCAGTATGCTTCCACCAGGC-3‟, Rev: 5‟-
AAGGGCTTCGAGGAATGTGAG-3‟), MAD2l1 (Frw: 5‟- 
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CTCATTCGGCATCAACAGCA- 3‟, Rev: 5‟- TCAGATGGATATATGCCACGCT-
3‟), AuroraA human (Frw: 5‟-TTTTGTAGGTCTCTTGGTATGTG-3‟, Rev: 5‟- 
GCTGGAGAGCTTAAAATTGCAG-3‟), DNMT3b (Frw: 5‟-
CAGACGTGTCCAACATGGGC-3‟, Rev: 5‟-GCCTTCAGGAATCACACCTC-3‟), 
CDKN3 (Frw: 5‟-CATAGCCAGCTGCTGTGA-3‟, Rev: 5‟-
CCCGGATCCTCTTAGGTCTC-3‟), p14ARF (Frw: 5‟-  
TGATGCTACTGAGGAGCCAGC-3‟, Rev: 5‟-AGGGCCTTTCCTACCTGGCTC-
3‟), BubR1 (Frw: 5‟-TACACTGGAAATGACCCTCTGGAT-3‟, Rev: 5‟- 
TATAATATCGTTTTTCTCCTTGTAGTGCTT-3‟). Data were analyzed by ave-
raging quadruplicates Ct (cycle threshold). Levels of RNA expression were de-
termined by using the SDS software version (Applied Biosystems) according to 
the 2-ΔΔct method. Levels of RNA expression of selected genes were norma-
lized to the internal control GAPDH. 
 
Western Blotting. 
Protein concentration was measured using the Bio-RadProtein Assay (Bio-Rad 
Laboratories). Proteins (40µg) were separated by 10% SDS-PAGE containing 
0,1% SDS and transferred to Hybond-C nitrocellulose membranes (Amersham 
Life Science) by electroblotting. The membranes were sequentially incubated 
with goat anti-DNMT1, rabbit anti-p21waf1, rabbit anti-pRb (Santa Cruz, CA), 
mouse anti-TP53 (ABCAM) as primary antibodies, and HRP-conjugated mouse, 
rabbit (ABCAM) and goat (Santa Cruz, CA) IgG as secondary antibodies. The 
target protein was detected with enhanced chemiluminescence Western blotting 
detection reagents (PIERCE). I used also mouse anti-β-tubulin (SIGMA, Italy) 
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as internal control of loading. Membranes were stained by Ponceau-Red to con-
firm equivalent loading of total protein in all lanes. 
 
Cell cycle analysis 
Asynchronously growing cells were treated with 80nM siDNMT1 alone or to-
gether with 60nM siTP53 for 72 hours and released into complete medium with 
Bromodeoxyuridine (BrdU) 0,2µg/ml for one hour. DNA content was determined 
using Propidium Iodide (PI) staining by treating cells with PBS solution contai-
ning 4µg/ml of PI and 40µg/ml RNase. Analysis of BrdU labelled cells was con-
ducted as described previously and samples were analyzed on a FACSCanto 
(Becton Dickinson). Experiments were repeated at least twice, 10000 events 
were analyzed by FACSDiva software. 
 
Cytogenetical analysis 
Cells were treated with 0,2µg/ml colcemid (Demecolcine, SIGMA, Italy) for 16 
hours. Cells were harvested by trypsinization, swollen in 75mM KCl at 37°C, 
fixed with 3:1 methanol/acetic acid (3:1 v/v), and dropped onto clean, ice-cold 
glass microscope slides. The slides were air-dried and stained with 3% 
GIEMSA in phosphate-buffered saline for 10 minutes. Chromosome numbers 
were evaluated using Zeiss Axioskop microscope under a 100X objective.  
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Immunofluorescence microscopy 
Phosphorylated H2A.X immunostaining: cells, both IMR90 and MCF10A, were 
grown on glass coverslips after siRNAs transfection. Coverslips were fixed with 
methanol at -20°C, permeabilized with 0.01% Triton X (Sigma, St. Louis, MO) 
and blocked with 0.1% BSA, both at room temperature. Then, coverslips were 
incubated with phosphorylated H2A.X rabbit polyclonal antibody (1:100 in PBS-
BSA 0.1%, Upstate) overnight at 4°C, washed in PBS and incubated with a 
FITC-conjugated rabbit anti-mouse (Sigma, diluted 1:100 in PBS-BSA 0,1%) for 
1 hour at 37°C. 
To detect centrosomes, 4 × 104 cells were grown on glass coverslips, fixed in 
methanol at -20°C, permeabilized with 0.01% Triton X (Sigma) and blocked with 
0.1% BSA both at room temperature. Then, coverslips were incubated with a 
mouse monoclonal antibody against -tubulin (Sigma, diluted 1:250 in PBS-BSA 
0,1%) overnight at 4°C, washed in PBS and incubated with a FITC-conjugated 
goat anti-mouse (Sigma, diluted 1:100 in PBS-BSA 0,1%) for 1 hour at 37°C.  
Nuclei were visualized with 1µg/ml of 4‟,6-Diamidino-2-phenylindole (DAPI) and 
examined on a Zeiss Axioskop microscope equipped for fluorescence, images 
were captured with a CCD digital camera (AxioCam, Zeiss). 
 
Methylation Specific PCR (MSP) 
Genomic DNA was extracted from cells by using the “All prep DNA/RNA kit” 
(Qiagen) according to the manufacture‟s instruction. DNA bisulfite modification 
was performed with ”Epitect Bisulfite kit” (Qiagen) according to the manufac-
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ture‟s instruction. Up to 1µg of genomic DNA was diluted to a total volume of 
140 µl with water, bisulfite mix and DNA protect buffer, and sodium bisulfite 
treatment was carried out for 5 hours alternating denaturation at 99°C and incu-
bation at 60°. Bisulfite- treated DNA samples were then purified with the “epitect 
column”, and desulfonated before precipitation in 20µl of “EB buffer”. 100ng of 
bisulfite-treated DNA was used for MSP. MSP primers were chosen to recog-
nize bisulfite-induced modifications of unmethylated cytosines. The primers se-
quences have been published previously for CHFR (19) (MCHFR For: 5‟- 
GTAATGTTTTTTGATAGCGGC-3‟, Rev: 5‟- AATCCCCCTTCGCCG-3‟; UCHFR 
For: 5‟- GGTTGTAATGTTTTTTGATAGTGGT-3‟, Rev: 5‟- 
CAAATCCCCCTTCACCA-3‟). The MSP utilized a 50µl reaction volume, 1,5U/μl 
Taq Gold, 1x Taq Gold Buffer, 0,2mM dNTPs, 1,5mM MgCl2, 0,5 μM Primers 
and 100ng of DNA template, and included 45 cycles at the following annealing 
temperatures: MCHFR, 58°C; UCHFR, 50°C. DNA isolated from SW480 cells 
served as a negative methylation control. MSP products were analyzed on 1,8% 
agarose gel electrophoresis, and were determined to have methylation if a visi-
ble band was observed in the methylation reaction. 
  
Global DNA methylation analysis 
“Methylamp Global DNA methylation quantification kit” (Epigentek) was used to 
quantify global DNA methylation. 200ng of genomic DNA extracted from cell 
samples was immobilized in the strip well specifically treated to have high affi-
nity to DNA for 2 hours at 37°C. The methylated fraction of DNA can be recog-
nized by sequential incubation with 5-methylcytosine antibody for 45 minutes at 
 
76 
37°C, and with secondary antibody for 60 minutes at room temperature. A co-
lorimetric reaction allowed methylated DNA quantification at 450nM with mi-
croplate reader.  A methylated DNA was used as positive control.  
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